RANI · Rani Therapeutics Holdings, Inc.

Rani Therapeutics reported transformative Q1 FY2026 results, with revenue leaping 893% year-over-year to $1.7 million from $172 thousand, primarily from contract revenue tied to the ProGen Collaboration Agreement. This surge validates the commercial potential of the RaniPill oral delivery platform for obesity treatments, as the January 2026 amendment enabled coordinated data disclosures and milestone recognition. Investors should note this reflects activation of partnership momentum rather than broad recurring sales, positioning Rani for future milestones contingent on clinical advancement.

Operating performance showed meaningful improvement, with operating loss narrowing 30.6% to -$8.3 million from -$12.0 million prior year. This reflects moderated development expenses relative to the prior period, even as the operating margin remained deeply negative at -488%. Net income followed suit, improving 3.2% to -$7.0 million from -$7.3 million, driving diluted EPS to -$0.04—a stark 81.8% enhancement from -$0.22. These dynamics underscore cost discipline amid Rani's focus on assets with alternative future use, where qualifying projects are capitalized as property and equipment while others are expensed as R&D.

Cash flow trends align with operational progress, as net cash used in operating activities eased to -$6.5 million from -$8.1 million. Capital expenditures were negligible at $15 thousand versus $51 thousand last year, resulting in free cash flow of -$6.5 million. This lean profile supports ongoing RaniPill development, though management highlights that the vertically integrated manufacturing strategy will drive material future capital outlays and fixed costs for facility construction and operations.

Looking forward, Rani expects to sustain operating losses and negative cash flows as it progresses the RaniPill capsule, with no dividend plans. These results signal positive trajectory in a pre-revenue biotech context, balancing revenue breakthroughs against persistent burn while emphasizing platform validation through partnerships.